The Food and Drug Administration (FDA) has posted a notice regarding the availability of Rescriptor Tablets (delavirdine mesylate; ViiV Healthcare). The manufacturer has decided to discontinue the product based on a business decision and not for safety reasons.
Rescriptor, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated for the treatment of HIV-1 infection in combination with at least two other active antiretroviral agents when therapy is warranted.
Both the 100mg and 200mg tablets have been discontinued. The anticipated final date for availability to patients is October 2018.
Current and Resolved Drug Shortages and Discontinuations Reported to FDA [press release]. Washington D.C.: Food and Drug Administration. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Delavirdine+Mesylate+%28RESCRIPTOR%29+Tablets&st=d&tab=tabs-4&panels=0 Last Updated May 11, 2017. Accessed May 30, 2017.
This article originally appeared on MPR